Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemoradiation in Resected Gastric or GEJ Adenocarcinoma
NCT00052910Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2002
- Primary completion
- Jun 2012
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of epirubicin and Cisplatin micelle injection (HA132) in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival at 3 years. Started Dec 2002; status: completed.
02
Drugs
epirubicinCisplatin micelle injection (HA132)
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00052910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052910.